FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W179710147> ?p ?o ?g. }

• W179710147 abstract "Abstract Introduction The human recombinant filgrastim G-CSF has been widely used for mobilisation of CD34+ cells of healthy donors (HD) since 90´s. In 2008, G-CSF biosimilars were approved by the European Medicines Agency for the same indications as those authorized for original filgrastim (Neupogen®). These new drugs were authorized on the basis of extensive physicochemical and biological protein characterization and pharmacodynamics data as well as clinical comparative studies in the particular field of chemotherapy–induced neutropenia in patients with solid tumors. Since then, the reported experience on the use of G-CSF biosimilars for PBSC mobilisation has been very limited particularly, in the setting of HD mobilization for allogeneic transplant. We report our single center experience on the use of filgrastim biosimilar Zarzio® (Sandoz Biopharmaceuticals®) for mobilization of HD, compared with a cohort of donors mobilized with the original filgrastim. Methods Retrospective comparative analysis of all consecutive HD undergoing a 1st attempt of PBSC mobilisation using 10 mcg/Kg/24h x4 days G-CSF (Filgrastim biosimilar Zarzio® [case cohort] or Filgrastim, Neupogen® [control cohort]) and collected with the same cellular separator (Cobe Spectra, Terumo®). Apheresis was initiated on day 5 and was daily repeated, if needed, in order to achive at least 3.5 x106/Kg patient body weight (PBW). SAEs were also analysed in both cohorts. For the porpoise of the post-transplant engraftment analysis both cohorts were independently compared according to the grade of HLA compatibility (HLA identical vs Haploidentical). Volunteer HD were excluded from the engraftment analysis. Non-parametric test was used for 2 cohorts comparison. Results Forty five HD cases and 41 controls undergoing G-CSF mobilization between June-09 and April-14 were eligible for the analysis. Donor features were comparable for both cohorts (table 1). Doses of G-CSF required, pre-apheresis analytical parameters, leukapheresis procedures, processed volume and collected graft parameters were found similar in both groups (table 1). All donors collected more than 2 x106/Kg CD34+ cells. Cummulative incidence of engraftment at day 30 was 100% for both cohorts, the HLA identical setting (p=0.53) and the haplo sub-group (p=0.25). AES were not observed for both cohorts. Conclusions In our experience, efficacy of G-CSF biosimilar Zarzio® was similar to reference filgrastim (Neupogen®) in terms of dose administered, CD34+ cells collected, stem cell functionality and engraftment. No SAEs were found for both cohorts. These preliminary results should be confirmed with a longer follow up within a prospective randomized trial. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare." @default.
• W179710147 created "2016-06-24" @default.
• W179710147 creator A5019880854 @default.
• W179710147 creator A5024036867 @default.
• W179710147 creator A5030257131 @default.
• W179710147 creator A5034694882 @default.
• W179710147 creator A5037711823 @default.
• W179710147 creator A5043991937 @default.
• W179710147 creator A5050429996 @default.
• W179710147 creator A5053872842 @default.
• W179710147 creator A5054200855 @default.
• W179710147 creator A5065173575 @default.
• W179710147 creator A5085957412 @default.
• W179710147 creator A5087835035 @default.
• W179710147 date "2014-12-06" @default.
• W179710147 modified "2023-10-18" @default.
• W179710147 title "Mobilisation of PBSC for Allogenic Transplantation By the Use of G-CSF Biosimilar Zarzio® in Healthy Donors" @default.
• W179710147 doi "https://doi.org/10.1182/blood.v124.21.5824.5824" @default.
• W179710147 hasPublicationYear "2014" @default.
• W179710147 type Work @default.
• W179710147 sameAs 179710147 @default.
• W179710147 citedByCount "1" @default.
• W179710147 countsByYear W1797101472019 @default.
• W179710147 crossrefType "journal-article" @default.
• W179710147 hasAuthorship W179710147A5019880854 @default.
• W179710147 hasAuthorship W179710147A5024036867 @default.
• W179710147 hasAuthorship W179710147A5030257131 @default.
• W179710147 hasAuthorship W179710147A5034694882 @default.
• W179710147 hasAuthorship W179710147A5037711823 @default.
• W179710147 hasAuthorship W179710147A5043991937 @default.
• W179710147 hasAuthorship W179710147A5050429996 @default.
• W179710147 hasAuthorship W179710147A5053872842 @default.
• W179710147 hasAuthorship W179710147A5054200855 @default.
• W179710147 hasAuthorship W179710147A5065173575 @default.
• W179710147 hasAuthorship W179710147A5085957412 @default.
• W179710147 hasAuthorship W179710147A5087835035 @default.
• W179710147 hasConcept C126322002 @default.
• W179710147 hasConcept C2776694085 @default.
• W179710147 hasConcept C2777063308 @default.
• W179710147 hasConcept C2778850193 @default.
• W179710147 hasConcept C2779171977 @default.
• W179710147 hasConcept C2911091166 @default.
• W179710147 hasConcept C59491497 @default.
• W179710147 hasConcept C71924100 @default.
• W179710147 hasConcept C72563966 @default.
• W179710147 hasConceptScore W179710147C126322002 @default.
• W179710147 hasConceptScore W179710147C2776694085 @default.
• W179710147 hasConceptScore W179710147C2777063308 @default.
• W179710147 hasConceptScore W179710147C2778850193 @default.
• W179710147 hasConceptScore W179710147C2779171977 @default.
• W179710147 hasConceptScore W179710147C2911091166 @default.
• W179710147 hasConceptScore W179710147C59491497 @default.
• W179710147 hasConceptScore W179710147C71924100 @default.
• W179710147 hasConceptScore W179710147C72563966 @default.
• W179710147 hasLocation W1797101471 @default.
• W179710147 hasOpenAccess W179710147 @default.
• W179710147 hasPrimaryLocation W1797101471 @default.
• W179710147 hasRelatedWork W1589047406 @default.
• W179710147 hasRelatedWork W2154836716 @default.
• W179710147 hasRelatedWork W2286122481 @default.
• W179710147 hasRelatedWork W2479590128 @default.
• W179710147 hasRelatedWork W2521239893 @default.
• W179710147 hasRelatedWork W2534956500 @default.
• W179710147 hasRelatedWork W2559911792 @default.
• W179710147 hasRelatedWork W2563401391 @default.
• W179710147 hasRelatedWork W2571123047 @default.
• W179710147 hasRelatedWork W2586799152 @default.
• W179710147 hasRelatedWork W2660387909 @default.
• W179710147 hasRelatedWork W2743213847 @default.
• W179710147 hasRelatedWork W2743347613 @default.
• W179710147 hasRelatedWork W2767605593 @default.
• W179710147 hasRelatedWork W2912694021 @default.
• W179710147 hasRelatedWork W2974713978 @default.
• W179710147 hasRelatedWork W3026020011 @default.
• W179710147 hasRelatedWork W31120536 @default.
• W179710147 hasRelatedWork W3198253307 @default.
• W179710147 hasRelatedWork W37935334 @default.
• W179710147 isParatext "false" @default.
• W179710147 isRetracted "false" @default.
• W179710147 magId "179710147" @default.
• W179710147 workType "article" @default.